JP2014525461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525461A5 JP2014525461A5 JP2014528651A JP2014528651A JP2014525461A5 JP 2014525461 A5 JP2014525461 A5 JP 2014525461A5 JP 2014528651 A JP2014528651 A JP 2014528651A JP 2014528651 A JP2014528651 A JP 2014528651A JP 2014525461 A5 JP2014525461 A5 JP 2014525461A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- motomeko
- rna
- liposome according
- immunogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims description 36
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 108010012057 RNA Replicase Proteins 0.000 claims description 2
- 108060006943 RdRp Proteins 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 244000045947 parasites Species 0.000 claims description 2
- 230000001681 protective Effects 0.000 claims description 2
- 230000001580 bacterial Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
- 101710006371 EIF2AK2 Proteins 0.000 description 4
- 102100011490 EIF2AK2 Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 1
- 108020004461 Double-Stranded RNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
Description
PKRは、二本鎖RNA依存性プロテインキナーゼである。これは、先天的免疫系において重要な役割を果たす。「EIF2AK2」(真核生物翻訳開始因子2−αキナーゼ2(eukaryotic translation initiation factor 2−alpha kinase 2)について)は、この酵素をコードする遺伝子の承認されたHGNC名であり、その特有のHGNC IDは、HGNC:9437である。ヒトPKR遺伝子のRefSeq配列は、GI:208431825である。
例えば、本発明は、以下の項目を提供する:
(項目1)
目的の免疫原をコードするRNAが被包されているリポソームであって、ここで該リポソームは、ポリエチレングリコールが該リポソームの外側に存在するようにポリエチレングリコール部分を含む少なくとも1種の脂質を含み、該ポリエチレングリコールの平均分子量は、3kDaより高いが11kDa未満である、リポソーム。
(項目2)
PEG−DMGおよび/もしくは式(X)の脂質を含む、項目1に記載のリポソーム。
(項目3)
上記リポソームは、80〜160nmの範囲の直径を有する、上述の項目のいずれかに記載のリポソーム。
(項目4)
上記リポソームは、カチオン性ヘッド基を有する脂質を含む、上述の項目のいずれかに記載のリポソーム。
(項目5)
上記リポソームは、両性イオン性ヘッド基を有する脂質を含む、上述の項目のいずれかに記載のリポソーム。
(項目6)
上記RNAは、自己複製RNAである、上述の項目のいずれかに記載のリポソーム。
(項目7)
上記自己複製RNA分子は、(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および(ii)免疫原をコードする、項目6に記載のリポソーム。
(項目8)
上記RNA分子は、2つのオープンリーディングフレームを有し、該オープンリーディングフレームのうちの第1のものは、アルファウイルスレプリカーゼをコードし、該オープンリーディングフレームのうちの第2のものは、上記免疫原をコードする、項目7に記載のリポソーム。
(項目9)
上記RNA分子は、9000〜12000ヌクレオチド長である、上述の項目のいずれかに記載のリポソーム。
(項目10)
上記免疫原は、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘発し得る、上述の項目のいずれかに記載のリポソーム。
(項目11)
上述の項目のいずれかに記載のリポソームを含む、薬学的組成物。
(項目12)
脊椎動物において防御免疫応答を惹起するための方法であって、該方法は、該脊椎動物に、有効量の、項目1〜10に記載のリポソームまたは項目11に記載の薬学的組成物を投与する工程を包含する、方法。
例えば、本発明は、以下の項目を提供する:
(項目1)
目的の免疫原をコードするRNAが被包されているリポソームであって、ここで該リポソームは、ポリエチレングリコールが該リポソームの外側に存在するようにポリエチレングリコール部分を含む少なくとも1種の脂質を含み、該ポリエチレングリコールの平均分子量は、3kDaより高いが11kDa未満である、リポソーム。
(項目2)
PEG−DMGおよび/もしくは式(X)の脂質を含む、項目1に記載のリポソーム。
(項目3)
上記リポソームは、80〜160nmの範囲の直径を有する、上述の項目のいずれかに記載のリポソーム。
(項目4)
上記リポソームは、カチオン性ヘッド基を有する脂質を含む、上述の項目のいずれかに記載のリポソーム。
(項目5)
上記リポソームは、両性イオン性ヘッド基を有する脂質を含む、上述の項目のいずれかに記載のリポソーム。
(項目6)
上記RNAは、自己複製RNAである、上述の項目のいずれかに記載のリポソーム。
(項目7)
上記自己複製RNA分子は、(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および(ii)免疫原をコードする、項目6に記載のリポソーム。
(項目8)
上記RNA分子は、2つのオープンリーディングフレームを有し、該オープンリーディングフレームのうちの第1のものは、アルファウイルスレプリカーゼをコードし、該オープンリーディングフレームのうちの第2のものは、上記免疫原をコードする、項目7に記載のリポソーム。
(項目9)
上記RNA分子は、9000〜12000ヌクレオチド長である、上述の項目のいずれかに記載のリポソーム。
(項目10)
上記免疫原は、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘発し得る、上述の項目のいずれかに記載のリポソーム。
(項目11)
上述の項目のいずれかに記載のリポソームを含む、薬学的組成物。
(項目12)
脊椎動物において防御免疫応答を惹起するための方法であって、該方法は、該脊椎動物に、有効量の、項目1〜10に記載のリポソームまたは項目11に記載の薬学的組成物を投与する工程を包含する、方法。
Claims (12)
- 目的の免疫原をコードするRNAが被包されているリポソームであって、ここで該リポソームは、ポリエチレングリコールが該リポソームの外側に存在するようにポリエチレングリコール部分を含む少なくとも1種の脂質を含み、該ポリエチレングリコールの平均分子量は、3kDaより高いが11kDa未満である、リポソーム。
- PEG−DMGおよび/もしくは式(X)の脂質を含む、請求項1に記載のリポソーム。
- 前記リポソームは、80〜160nmの範囲の直径を有する、請求項1〜2のいずれかに記載のリポソーム。
- 前記リポソームは、カチオン性ヘッド基を有する脂質を含む、請求項1〜3のいずれかに記載のリポソーム。
- 前記リポソームは、両性イオン性ヘッド基を有する脂質を含む、請求項1〜4のいずれかに記載のリポソーム。
- 前記RNAは、自己複製RNAである、請求項1〜5のいずれかに記載のリポソーム。
- 前記自己複製RNA分子は、(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および(ii)免疫原をコードする、請求項6に記載のリポソーム。
- 前記RNA分子は、2つのオープンリーディングフレームを有し、該オープンリーディングフレームのうちの第1のものは、アルファウイルスレプリカーゼをコードし、該オープンリーディングフレームのうちの第2のものは、前記免疫原をコードする、請求項7に記載のリポソーム。
- 前記RNA分子は、9000〜12000ヌクレオチド長である、請求項1〜8のいずれかに記載のリポソーム。
- 前記免疫原は、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘発し得る、請求項1〜9のいずれかに記載のリポソーム。
- 請求項1〜10のいずれかに記載のリポソームを含む、薬学的組成物。
- 脊椎動物において防御免疫応答を惹起するための、有効量の請求項1〜10に記載のリポソームを含む組成物または請求項11に記載の薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529878P | 2011-08-31 | 2011-08-31 | |
US61/529,878 | 2011-08-31 | ||
PCT/US2012/053391 WO2013033563A1 (en) | 2011-08-31 | 2012-08-31 | Pegylated liposomes for delivery of immunogen-encoding rna |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014525461A JP2014525461A (ja) | 2014-09-29 |
JP2014525461A5 true JP2014525461A5 (ja) | 2015-10-15 |
Family
ID=47003206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014528651A Pending JP2014525461A (ja) | 2011-08-31 | 2012-08-31 | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
Country Status (21)
Country | Link |
---|---|
US (3) | US20140255472A1 (ja) |
EP (2) | EP3508220A1 (ja) |
JP (1) | JP2014525461A (ja) |
CN (1) | CN103974719A (ja) |
AU (1) | AU2012301715B2 (ja) |
BR (1) | BR112014004607A2 (ja) |
CA (1) | CA2846043A1 (ja) |
CY (1) | CY1121122T1 (ja) |
DK (1) | DK2750707T3 (ja) |
ES (1) | ES2705498T3 (ja) |
HR (1) | HRP20190032T1 (ja) |
HU (1) | HUE041800T2 (ja) |
LT (1) | LT2750707T (ja) |
MX (1) | MX366055B (ja) |
PL (1) | PL2750707T3 (ja) |
PT (1) | PT2750707T (ja) |
RU (1) | RU2628705C2 (ja) |
SG (2) | SG11201400250UA (ja) |
SI (1) | SI2750707T1 (ja) |
TR (1) | TR201900264T4 (ja) |
WO (1) | WO2013033563A1 (ja) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3169291A1 (en) | 2010-07-06 | 2012-01-12 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of rna |
EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
CN106421773A (zh) | 2010-07-06 | 2017-02-22 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SI4008357T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
HRP20221533T1 (hr) | 2010-08-31 | 2023-02-17 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
MX363307B (es) * | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Plataformas para suministro de antigenos. |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
CA3107288A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
JP2015522581A (ja) * | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | サイトメガロウイルスタンパク質の複合体 |
EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
WO2014108515A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
ES2774968T3 (es) | 2013-12-19 | 2020-07-23 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
EP3122774B1 (en) | 2014-03-25 | 2020-11-04 | Yale University | Uses of parasite macrophage migration inhibitory factors |
JP2017510662A (ja) | 2014-04-08 | 2017-04-13 | アラダイム コーポレーション | 非結核性抗酸菌に対する活性を有するリポソームシプロフロキサシン製剤 |
KR20160144404A (ko) | 2014-04-08 | 2016-12-16 | 아라다임 코포레이션 | 냉동-해동 후 약물 나노결정을 형성하는 리포솜 |
SI3134131T1 (sl) | 2014-04-23 | 2022-04-29 | Modernatx, Inc. | Cepiva na osnovi nukleinskih kislin |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
JP2017524357A (ja) | 2014-07-16 | 2017-08-31 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | キメラポリヌクレオチド |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
EP3736261B1 (en) | 2015-09-17 | 2023-10-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
CN108601823A (zh) * | 2015-09-23 | 2018-09-28 | 麻省理工学院 | 用于改性树枝状聚合物纳米颗粒疫苗递送的组合物和方法 |
AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
ES2913626T3 (es) | 2015-12-22 | 2022-06-03 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes |
WO2017123315A2 (en) * | 2016-01-12 | 2017-07-20 | Aradigm Corporation | Nanocrystals formed in a microenvironment |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
EP3458034A4 (en) | 2016-05-18 | 2020-01-01 | ModernaTX, Inc. | POLYNUCLEOTIDS FOR THE CODING OF RELAXIN |
WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
US11780885B2 (en) | 2016-11-17 | 2023-10-10 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
AU2017397458A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | RNA cancer vaccines |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
US11504421B2 (en) | 2017-05-08 | 2022-11-22 | Gritstone Bio, Inc. | Alphavirus neoantigen vectors |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
US10988754B2 (en) | 2017-07-04 | 2021-04-27 | Cure Vac AG | Nucleic acid molecules |
WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019046809A1 (en) * | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
CA3074919A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
US20200277627A1 (en) | 2017-09-13 | 2020-09-03 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
CA3084833A1 (en) * | 2017-12-06 | 2019-06-13 | Newsouth Innovations Pty Limited | Liposomal system for drug delivery |
SG11202006400UA (en) | 2018-01-04 | 2020-08-28 | Iconic Therapeutics Inc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
JP2021534182A (ja) | 2018-08-17 | 2021-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物及びその使用 |
CN113166783A (zh) | 2018-10-09 | 2021-07-23 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
US20220062439A1 (en) | 2019-01-10 | 2022-03-03 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
EP3976075A4 (en) | 2019-05-30 | 2023-08-16 | Gritstone bio, Inc. | MODIFIED ADENOVIRUS |
MA56520A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Construction de l'interleukine 12 recombinante et ses utilisations |
WO2020255009A2 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
CN114340664A (zh) | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合 |
CN114630675A (zh) | 2019-06-18 | 2022-06-14 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合 |
WO2020255062A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
BR112022000710A2 (pt) | 2019-07-21 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Vacina viral terapêutica |
CN114728887A (zh) | 2019-09-19 | 2022-07-08 | 摩登纳特斯有限公司 | 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物 |
EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
CA3171219A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
JP2023520764A (ja) | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | 第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用 |
JP2023520763A (ja) | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | ゴーシェ治療薬を発現するための非ウイルス性dnaベクター及びその使用 |
WO2021209970A1 (en) | 2020-04-16 | 2021-10-21 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
US20230265454A1 (en) | 2020-06-04 | 2023-08-24 | BioNTech SE | RNA Replicon for Versatile and Efficient Gene Expression |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
WO2022002783A1 (en) | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
EP4267593A2 (en) | 2020-12-23 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Self-amplifying messenger rna |
AU2021412833A1 (en) | 2020-12-28 | 2023-07-06 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024511206A (ja) | 2021-03-26 | 2024-03-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
EP4321504A1 (en) * | 2021-04-08 | 2024-02-14 | Xiamen Sinopeg Biotech Co., Ltd. | Pegylated lipid and liposome modified thereby, and pharmaceutical composition comprising liposome and preparation and use thereof |
JP2024517427A (ja) | 2021-04-20 | 2024-04-22 | アンジャリウム バイオサイエンシズ エージー | アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法 |
EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
IL308404A (en) | 2021-04-27 | 2024-01-01 | Generation Bio Co | Non-viral DNA vectors expressing therapeutic antibodies and uses thereof |
WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
CA3234396A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
CA3234214A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
CA3236235A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
WO2024119074A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
EP1541690A3 (en) * | 1999-09-09 | 2005-07-27 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
CA2411542A1 (en) | 2000-06-09 | 2001-12-13 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
JP4254931B1 (ja) | 2000-10-27 | 2009-04-15 | カイロン ソチエタ ア レスポンサビリタ リミタータ | A群連鎖球菌およびb群連鎖球菌由来の核酸およびタンパク質 |
WO2003018054A1 (en) | 2001-08-31 | 2003-03-06 | Chiron Srl. | Helicobacter pylori vaccination |
JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
BRPI0411857A (pt) | 2003-06-26 | 2006-05-23 | Chiron Corp | composições imunogênicas para chlamydia trachomatis |
PT1648500E (pt) | 2003-07-31 | 2014-10-10 | Novartis Vaccines & Diagnostic | Composições imunogénicas para estreptococos piogenes |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
JP5065024B2 (ja) | 2004-05-18 | 2012-10-31 | アルファバックス,インコーポレイティド | Tc−83由来アルファウイルスベクター、粒子および方法 |
WO2005120152A2 (en) * | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
CN101687025A (zh) | 2005-03-30 | 2010-03-31 | 诺华疫苗和诊断公司 | B型流感嗜血杆菌 |
RU2007146137A (ru) | 2005-05-12 | 2009-06-27 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Иммуногенные композиции на основе chlamydia trachomatis |
US7776336B2 (en) | 2005-10-25 | 2010-08-17 | Novartis Vaccines And Diagnostics Srl | Compositions comprising Yersinia pestis antigens |
WO2007149518A2 (en) * | 2006-06-21 | 2007-12-27 | The Scripps Research Institute | Dna composition against tumor stromal antigen fap and methods of use thereof |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
EP2224912B1 (en) * | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
EP2268659A2 (en) | 2008-03-06 | 2011-01-05 | Novartis AG | Mutant forms of chlamydia htra |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
AU2010208035B2 (en) * | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
SG178026A1 (en) * | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
EP3072881A1 (en) * | 2009-08-20 | 2016-09-28 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
KR20120128598A (ko) | 2009-11-04 | 2012-11-27 | 마리나 바이오테크, 인크. | 활성 생성 전달 분자들 |
CA3009891C (en) * | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
WO2011149733A2 (en) * | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
CN106421773A (zh) | 2010-07-06 | 2017-02-22 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
HRP20221533T1 (hr) | 2010-08-31 | 2023-02-17 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
SI4008357T1 (sl) * | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
US8584462B2 (en) * | 2011-07-21 | 2013-11-19 | Kalex, Llc | Process and power system utilizing potential of ocean thermal energy conversion |
-
2012
- 2012-08-31 AU AU2012301715A patent/AU2012301715B2/en active Active
- 2012-08-31 TR TR2019/00264T patent/TR201900264T4/tr unknown
- 2012-08-31 CN CN201280052386.XA patent/CN103974719A/zh active Pending
- 2012-08-31 EP EP18201799.6A patent/EP3508220A1/en active Pending
- 2012-08-31 SG SG11201400250UA patent/SG11201400250UA/en unknown
- 2012-08-31 WO PCT/US2012/053391 patent/WO2013033563A1/en active Application Filing
- 2012-08-31 ES ES12769787T patent/ES2705498T3/es active Active
- 2012-08-31 EP EP12769787.8A patent/EP2750707B1/en not_active Revoked
- 2012-08-31 SI SI201231501T patent/SI2750707T1/sl unknown
- 2012-08-31 PL PL12769787T patent/PL2750707T3/pl unknown
- 2012-08-31 CA CA 2846043 patent/CA2846043A1/en active Pending
- 2012-08-31 DK DK12769787.8T patent/DK2750707T3/en active
- 2012-08-31 HU HUE12769787A patent/HUE041800T2/hu unknown
- 2012-08-31 BR BR112014004607A patent/BR112014004607A2/pt not_active Application Discontinuation
- 2012-08-31 US US14/240,020 patent/US20140255472A1/en not_active Abandoned
- 2012-08-31 MX MX2014002203A patent/MX366055B/es active IP Right Grant
- 2012-08-31 SG SG10201602456WA patent/SG10201602456WA/en unknown
- 2012-08-31 RU RU2014112220A patent/RU2628705C2/ru active
- 2012-08-31 PT PT12769787T patent/PT2750707T/pt unknown
- 2012-08-31 LT LTEP12769787.8T patent/LT2750707T/lt unknown
- 2012-08-31 JP JP2014528651A patent/JP2014525461A/ja active Pending
-
2019
- 2019-01-04 HR HRP20190032TT patent/HRP20190032T1/hr unknown
- 2019-01-15 CY CY191100050T patent/CY1121122T1/el unknown
- 2019-12-16 US US16/714,877 patent/US20200113830A1/en not_active Abandoned
-
2023
- 2023-02-27 US US18/114,434 patent/US20240016736A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014525461A5 (ja) | ||
JP2013537518A5 (ja) | ||
RU2013114392A (ru) | Маленькие липосомы для доставки кодирующей иммуноген рнк | |
JP2014520806A5 (ja) | ||
Sandbrink et al. | RNA vaccines: a suitable platform for tackling emerging pandemics? | |
Chahal et al. | Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose | |
JP2013533747A5 (ja) | ||
Lundstrom | Replicon RNA viral vectors as vaccines | |
Cornelissen et al. | A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1 | |
WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
JP2014505007A5 (ja) | ||
HRP20220695T1 (hr) | Pegilirani liposomi za isporuku rnk kodirane za imunogen | |
WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
CA2856891C (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen | |
RU2013114330A (ru) | Липиды, подходящие для липосомной доставки кодирующей белок рнк | |
WO2013143700A3 (en) | Artificial nucleic acid molecules comprising a 5'top utr | |
WO2009105152A3 (en) | Virus-like particles as vaccines for paramyxovirus | |
WO2011140595A3 (en) | Immunostimulatory and vaccine compositions | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
BR112015006763B1 (pt) | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante | |
WO2015052543A3 (en) | Malaria vaccination | |
WO2008103819A3 (en) | Chimeric newcastle disease virus vlps | |
BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." |